argenx (ARGX) Stock Forecast & Price Target

Argenx exhibits a strong growth trajectory, highlighted by impressive topline revenue, which reached $790 million in Q1 2025 and $949 million in Q2 2025, reflecting significant year-over-year increases of approximately 98% and 97%, respectively. The company's innovative pre-filled syringe formulation has accelerated adoption, contributing to a growing prescriber base with around 1,000 prescribers reported in Q2, including 150 new to Vyvgart, and driving meaningful uptake in both generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Additionally, promising data from the Phase Ib DOK7-CMS study support the advancement of ARGX-119 toward a Phase III trial, suggesting robust pipeline potential that could further enhance Argenx's market position in treating rare autoimmune diseases.

Argenx faces several fundamental risks that could negatively impact its stock performance, including lower-than-anticipated sales growth for Vyvgart and potential safety concerns associated with its lead product efgartigimod. Additionally, the company's future outlook may be hampered by the emergence of new competitors and various macroeconomic factors, such as inflation and supply chain issues, that could affect operational efficiency and profitability. Furthermore, reliance on continued success in its ongoing research and development projects poses significant uncertainty, particularly with its ambitious target penetration rates in niche markets like Chronic Inflammatory Demyelinating Polyneuropathy and ocular myasthenia gravis.